1. Clinical & Scientific Overview
Chlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub) (TIP-MED-000260, Reference Code [12.28]) is classified under
Dermatological & Topical Antiseptic Preparations (Ch 12) as a Cationic Bisbiguanide Antiseptic & Disinfectant (Persistent Residual Substantivity).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.28], p. 168): Hexidine, Clohex, Rexidin (Mouthwash 0.2%), Savlon (with Cetrimide), Microshield (2%/4%) — Strengths & Dosage Forms: Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
3. Mechanism of Action & Pharmacodynamics
Positively charged cationic molecule binds strongly to negatively charged bacterial cell walls and oral/cutaneous strata -> disrupts cytoplasmic membranes and binds to skin/mucosa providing persistent residual antimicrobial activity ('substantivity') for >=6 hours.
4. Therapeutic Indications & Evidence-Supported Uses
- Gingivitis, oral mucositis, and periodontal plaque control (0
- 12-0
- 2% mouthwash)
- neonatal umbilical cord care (7
- 1% chlorhexidine digluconate delivering 4% chlorhexidine)
- pre-operative skin prep and central-line antisepsis (2% in 70% isopropyl alcohol)
- surgical hand scrub (4%)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Mouthwash (0.2%): Rinse thoroughly with 10 mL undiluted for 1 full minute twice daily and spit out. Skin / Central-Line Prep: Apply 2% alcoholic solution and allow to dry completely before venepuncture/cautery. • Paediatric: Neonatal Umbilical Cord Care (in high-mortality home-birth settings): Apply 4% chlorhexidine daily to umbilical stump during first week of life.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Not applicable. • Hepatic: Not applicable.
Renal: Not applicable. • Hepatic: Not applicable.
Renal: Not applicable. • Hepatic: Not applicable.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Direct contact with the brain, meninges, middle ear (perforated tympanic membrane—causes sensorineural deafness!), or eyes (concentrations >0.05% cause severe irreversible corneal endothelial toxicity). • Precautions: Cationic chlorhexidine is inactivated by anionic surfactants—specifically SODIUM LAURYL SULPHATE (SLS) present in almost all standard toothpastes and soaps! Wait at least 30 minutes after brushing teeth with toothpaste before using Chlorhexidine mouthwash. Never put Neonatal 4% Chlorhexidine Umbilical Gel/Drops into the infant's eyes!
Key Clinical Precautions: Renal: Not applicable. • Hepatic: Not applicable.
8. Adverse Effects Profile
- Reversible extrinsic brown staining of teeth, tongue, and silicate fillings; transient dysgeusia (altered taste/burning tongue); increased tartar.
- Rare severe IgE-mediated anaphylaxis (especially from chlorhexidine-coated central venous or urinary catheters), corneal ulceration, ototoxicity.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Sodium Lauryl Sulphate (toothpaste) / Soaps / Povidone-iodine / Hypochlorite bleach -> chemical precipitation and inactivation (chlorhexidine + bleach on hospital linen produces permanent dark brown stains)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Wait at least 30 minutes AFTER brushing teeth with toothpaste before rinsing with Chlorhexidine mouthwash (toothpaste neutralises the medicine); rinse for 60 seconds, spit out, and do not eat or drink for 30 minutes after.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: OTC / Non-Schedule | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.28] (p. 168)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.6]-C154 Ketoconazole / Clindamycin Topical Preparations — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.6]-CMP155 Adapalene 0.1% Gel, Benzoyl Peroxide 2.5%–5% Gel & Luliconazole 1% — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.23]-CMP168 Gamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol — Topical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pedicu
- [12.26]-C169 Clobetasol Propionate — Potent (Class II/III) Fluorinated Topical Corticosteroid